Log In Sign up
The largest database of trusted experimental protocols

Ab58201

Manufactured by Abcam
Visit Supplier
Sourced in United Kingdom

Ab58201 is a lab equipment product. It is designed for laboratory use. The core function of this product is to [description not available].

Automatically generated - may contain errors

Lab products found in correlation

Ab166987, by Abcam (2 mentions) Hpa043605, by Atlas Antibodies (2 mentions) Histo ne kit, by Nichirei Biosciences (2 mentions) Rabbit anti pd l1, by Cell Signaling Technology (1 mentions) Envision plus detection system, by Agilent Technologies (1 mentions) Bond 3, by Leica (1 mentions) Nat105, by Cell Marque (1 mentions)

8 protocols using ab58201

1

Immunodetection of FGFR2, PD-L1, and HER2

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary antibodies in this study are as follows: mouse anti-FGFR2 (ab58201, Abcam, Cambridge, MA), and rabbit anti-PD-L1 (#13684) and rabbit anti-HER2/ErbB2 (#4290) (Cell Signaling Technology, Denver, MA).
Titapun A., Techasen A., Sa-Ngiamwibool P., Sithithaworn P., Luvira V., Srisuk T., Jareanrat A., Dokduang H., Loilome W., Thinkhamrop B, & Khuntikeo N. (2020). Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression. International Journal of General Medicine, 13, 1271-1283.
+ Open protocol
+ Expand
2

FGFR2 IHC Scoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
FGFR2 IHC staining was performed manually as previously published using a non‐isoform‐specific anti‐FGFR2 antibody (Cat# Ab58201, Abcam, Cambridge, UK) [11 (link)]. IHC was scored using two parameters; intensity of stain and percentage of positive tumor cells using a semi‐quantitative immune‐reactivity histologic scoring method (H‐score) as previously published [11 (link), 19 (link)]. In brief, H‐score was calculated as follows: H‐score = ∑(PI1−3), where P is the percentage of positive tumor cells, I is the intensity of staining (I1 – weak, I2 – moderate, and I3 – strong intensity), and the maximum H‐score is 300.
Sengal A.T., Smith D., Snell C.E., Leung S., Talhouk A., Williams E.D., McAlpine J.N, & Pollock P.M. (2022). Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. The Journal of Pathology: Clinical Research, 8(6), 521-537.
+ Open protocol
+ Expand
3

Immunohistochemical Staining of FGFR2 in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemical (IHC) staining was performed on 4-μm FFPE sections. Each section was autoclaved in 10 mmol/L citrate buffer (pH 6.0) for 15 min, and endogenous peroxidase activity was blocked by adding 3% hydrogen peroxide for 5 min. The sections were then incubated overnight with 1:1000 (in 0.1 mol/L phosphate-buffered saline) diluted primary mouse monoclonal anti-FGFR2 antibody (ab58201, Abcam, Cambridge, UK) at 4°C, followed by incubation with a biotin-free horseradish peroxidase-labeled polymer (Envision Plus detection system; Dako, Glostrup, Denmark) for 1 h at room temperature. The reaction was visualized by diaminobenzidine solution and hematoxylin counterstaining. Two pathologists (YI and YN, who were blinded to the other data) recorded the membranous and cytoplasmic FGFR2 expression in the cancer cell, scoring absent, faint, moderate, or strong staining, respectively. FGFR2-IHC positive was assigned for the cases with moderate-strong staining, and negative for those with absent or faint staining, which was the same as previously reported [35 (link)]. The value of kappa was 0.91 (P < 0.001), indicating almost perfect agreement. For positive cases, we also scored percentage of positivity in the tumor. The concordance between the two observers was measured using kappa statistics.
Tokunaga R., Imamura Y., Nakamura K., Ishimoto T., Nakagawa S., Miyake K., Nakaji Y., Tsuda Y., Iwatsuki M., Baba Y., Sakamoto Y., Miyamoto Y., Saeki H., Yoshida N., Oki E., Watanabe M., Oda Y., Bass A.J., Maehara Y, & Baba H. (2016). Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget, 7(15), 19748-19761.
+ Open protocol
+ Expand
4

FGFR2 Immunohistochemistry Scoring Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Specimens used for the CNV analysis were also used for immunohistochemical staining. Immunostaining was performed with an automated stainer (Leica Bond-III, Leica, Tokyo, Japan) using a heat-based antigen retrieval technique with BOND Epitope Retrieval Solution 1 for 20 min at 100 °C according to the manufacturer's protocol. A mouse monoclonal antibody against human FGFR2 (ab58201; Abcam, Cambridge, UK) was used at a dilution of 500. FGFR2 expression was scored using the intensity of staining and the percentage of stained tumor cells as follows: Score 1, < 80% of tumor cells strongly expressed, and Score 2, ≥ 80% of tumor cells strongly expressed. Strong FGFR2 expression was scored when cytoplasmic or membranous staining was stronger than that in normal gastric epithelium in the same section.
Hatakeyama K., Muramatsu K., Nagashima T., Ichida H., Kawanishi Y., Fukumura R., Ohshima K., Shimoda Y., Ohnami S., Ohnami S., Maruyama K., Naruoka A., Kenmotsu H., Urakami K., Akiyama Y., Sugino T, & Yamaguchi K. (2024). Tumor cell enrichment by tissue suspension improves sensitivity to copy number variation in diffuse gastric cancer with low tumor content. Scientific reports, 14(1).
+ Open protocol
+ Expand
5

Evaluating Cell Adhesion Receptors in hMSC

Check if the same lab product or an alternative is used in the 5 most similar protocols
hMSCs seeded on nHA-PCLUR films were stained for PiT1 (ab237527, Abcam), PiT2 (sc-377326, Santa Cruz Biotechnology), and FGFR2 (ab58201, Abcam). Primary antibodies were applied at 1:100 dilution overnight at 4°C. Detection via confocal microscopy (Carl Zeiss 710) was performed using secondary antibodies labeled with Alexa Flour 488 and Alexa Flour 568 at 1:200 dilution. Immunofluorescent intensity analysis was performed with FIJI Image J (NIH) and measured as corrected total cell fluorescence. Photobleaching FRET experiments with PiT1(Alexa Flour 488) and FGFR2 (Alexa Flour 568) were performed by exciting the fluor with the 561 nm laser 300 times with 100% laser power. The fluorescence intensity of the donor fluor was measured before and after photobleaching of the acceptor, and energy transfer efficiency was calculated using these values.
Boller L.A., Shiels S.M., Florian D.C., Peck S., Schoenecker J.G., Duvall C., Wenke J.C, & Guelcher S.A. (2021). Effects of Nanocrystalline Hydroxyapatite Concentration and Skeletal Site on Bone and Cartilage Formation in Rats. Acta biomaterialia, 130, 485-496.
+ Open protocol
+ Expand
6

Immunohistochemical Analysis of Tumor Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
The expression of PD-1, PD-L1, CD3, FGFR2 in tumors was evaluated via immunohistochemical analysis (anti-PD-1, 1:100, NAT105, Cell Marque; anti-PD-L1, 1:100, SP142, Spring Bio; anti-CD3, 1:500, CD3-565-L-CE, Leica/Novocastra; anti-FGFR2, 1:200, ab58201, Abcam). The PD-1, PD-L1 is observable in the cytoplasm or on the membrane of the tumor cell or the TILs. The immunoreactivity of PD-1, PD-L1 was evaluated semiquantitatively according to the percentage and intensity of positive cells. Specimens in which PD-1 or PD-L1 were observed in more than 1% of tumor cells or immune cells were considered PD-1 or PD-L1 positive. CD3 was detected in the nuclei of the TILs. The distribution of CD3+ TILs was observed in the areas with the highest density of TILs first at low magnification. The amount of positive TILs was then recorded at high magnification (HPF 400× magnification). The number of CD3+ TILs was determined in 30 random high power fields in each section.
Wang Y., Shi T., Wang X., Hu J., Yu L., Liu Q., Wu N., Liu B, & Wei J. (2021). FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma. Journal of Translational Medicine, 19, 401.
+ Open protocol
+ Expand
7

Immunohistochemical Analysis of GLP-1R, FGF7, and FGFR2

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four-micron tissue sections prepared from 10% formalin-xed and para n-embedded tissues of the representative areas of the lesions were prepared in this study. A mouse monoclonal antibody against GLP-1R (ab166987, abcam, Cambridge UK), a rabbit polyclonal antibody against FGF7 (HPA043605, Atlas Antibodies, Stockholm Sweden) and a mouse monoclonal antibody against FGFR2 (ab58201, abcam, Cambridge UK) were used as primary antibodies in this study as summarized in Table 2. After depara nization and hydration, the antigen retrieval was performed with citrate buffer using microwave irradiation for 20 minutes in GLP-1R and with autoclave at 121 C for 5 minutes in FGFR2 and FGF7. The slides were then incubated for 18 hours with primary antibodies against GLP-1R, FGF7 and FGFR2. Histo ne kit (Nichirei Bioscience, Tokyo, Japan) was used for immunostaining. DAB was used as colorimetric agent for 15 minutes in GLP-1R and FGF7 immunostaining, and for 10 minutes in FGFR2 at room temperature. The tissue slides were nally counterstained with hematoxylin. The positive controls were pancreatic islets of Langerhans in GLP-1R, urinary bladder urothelial carcinoma in FGF7 and pulmonary adenocarcinoma in FGFR2. Negative controls were treated with 1% BSA in PBS instead of the primary antibody. An absorption test with excessive antigens was performed in FGF7 immunostaining.
Hashimoto Takigami N., Kuniyoshi S., Miki Y., Tamaki K., Kamada Y., Uehara K., Tsuchiya S., Terukina S., Iwabuchi E., Kanai A., Miyashita M., Ishida T., Tamaki N, & Sasano H. (2021). Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations. Breast cancer research and treatment, 189(1).
+ Open protocol
+ Expand
8

Immunohistochemical Analysis of GLP-1R, FGF7, and FGFR2

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four-micron tissue sections prepared from 10% formalin-xed and para n-embedded tissues of the representative areas of the lesions were prepared in this study. A mouse monoclonal antibody against GLP-1R (ab166987, abcam, Cambridge UK), a rabbit polyclonal antibody against FGF7 (HPA043605, Atlas Antibodies, Stockholm Sweden) and a mouse monoclonal antibody against FGFR2 (ab58201, abcam, Cambridge UK) were used as primary antibodies in this study as summarized in Table 2. After depara nization and hydration, the antigen retrieval was performed with citrate buffer using microwave irradiation for 20 minutes in GLP-1R and with autoclave at 121 C for 5 minutes in FGFR2 and FGF7. The slides were then incubated for 18 hours with primary antibodies against GLP-1R, FGF7 and FGFR2. Histo ne kit (Nichirei Bioscience, Tokyo, Japan) was used for immunostaining. DAB was used as colorimetric agent for 15 minutes in GLP-1R and FGF7 immunostaining, and for 10 minutes in FGFR2 at room temperature. The tissue slides were nally counterstained with hematoxylin. The positive controls were pancreatic islets of Langerhans in GLP-1R, urinary bladder urothelial carcinoma in FGF7 and pulmonary adenocarcinoma in FGFR2. Negative controls were treated with 1% BSA in PBS instead of the primary antibody. An absorption test with excessive antigens was performed in FGF7 immunostaining.
Takigami N., Kuniyoshi S., Miki Y., Tamaki K., Kamada Y., Uehara K., Tsuchiya S., Terukina S., Iwabuchi E., Kanai A., Miyashita M., Ishida T., Tamaki N., & Sasano H. (2021). Breast Cancer, Diabetes Mellitus And Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!